Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29136259 | 1.00 | MPI (0.43) | MPIPTPN1AKR1B1 | |
| SCHEMBL1672719 | 1.00 | MPI (0.43) | MPIPTPN1AKR1B1 | |
| SCHEMBL354744 | 1.00 | MPI (0.43) | MPIPTPN1AKR1B1 | |
| SCHEMBL25379492 | 0.94 | MPI (0.44) | MPIPTPN1AKR1B1 | |
| SCHEMBL10798200 | 0.86 | MPI (0.47) | MPIPTPN1AKR1B1 | |
| SCHEMBL2793748 | 0.86 | MPI (0.39) | MPI | |
| SCHEMBL4581133 | 0.86 | MPI (0.39) | MPI | |
| SCHEMBL6811678 | 0.86 | MPI (0.39) | MPI | |
| SCHEMBL8027872 | 0.86 | MPI (0.39) | MPI | |
| SCHEMBL8067527 | 0.86 | MPI (0.39) | MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092264-A1 | NOVEL PROCESS FOR PURIFYING HEPARAN-N-SULFATASE | GREEN CROSS CORP (KR) | 2026-04-02 | — | — | US | disclosed |
| EP-4590811-A1 | NOVEL PROCESS FOR PURIFYING HEPARAN-N-SULFATASE | GREEN CROSS CORPORATION (KR) | 2025-07-30 | — | — | EP | disclosed |
| CN-119790147-A | New method for purifying heparan-N-sulfatase | 株式会社绿十字 | 2025-04-08 | — | — | CN | disclosed |
| WO-2024063469-A1 | NOVEL PROCESS FOR PURIFYING HEPARAN-N-SULFATASE | GREEN CROSS CORPORATION (KR) | 2024-03-28 | — | — | WO | disclosed |
| EP-3351270-A1 | TARGETED CARRIERS FOR INTRACELLULAR DRUG DELIVERY | The Trustees of the University of Pennsylvania (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-2164989-B1 | TARGETED CARRIERS FOR INTRACELLULAR DRUG DELIVERY | UNIV PENNSYLVANIA (US) | 2018-01-24 | — | — | EP | disclosed |
| US-20170296675-A1 | TARGETED CARRIERS FOR INTRACELLULAR DRUG DELIVERY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-10-19 | — | — | US | disclosed |
| US-9707299-B2 | Targeted carriers for intracellular drug delivery | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-07-18 | — | — | US | disclosed |
| US-20100151005-A1 | TARGETED CARRIERS FOR INTRACELLULAR DRUG DELIVERY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2010-06-17 | — | — | US | disclosed |
| EP-2164989-A1 | TARGETED CARRIERS FOR INTRACELLULAR DRUG DELIVERY | The Trustees of the University of Pennsylvania (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008147526-A1 | TARGETED CARRIERS FOR INTRACELLULAR DRUG DELIVERY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-12-04 | — | — | WO | disclosed |
| EP-1007533-B1 | BIOCONJUGATES AND DELIVERY OF BIOACTIVE AGENTS | UNIV UTAH RES FOUND (US) | 2005-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092264-A1 | NOVEL PROCESS FOR PURIFYING HEPARAN-N-SULFATASE | HPSE, ENGASE, MAN2B1 | MPI 74/4885PTPN1 333/4885AKR1B1 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.